What is the main purpose of this 8-K filing?

This 8-K filing announces that Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. It also provides details on how investors can access further information about the transaction, including a press release, investor presentation, and upcoming conference call.

What are the key terms of the acquisition of Penumbra?

The filing states that BSX has executed a definitive agreement to acquire Penumbra, Inc. on terms and subject to conditions outlined in the agreement. Specific financial terms or the purchase price are not disclosed in this 8-K, but will be detailed in subsequent filings and investor materials.

What steps will follow this announcement?

Boston Scientific will file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus for Penumbra's stockholders. This document will contain essential details about the transaction. BSX will also hold a conference call and has made an investor presentation available.

Where can investors find more detailed information about the acquisition?

Investors can find more detailed information on the SEC's website (www.sec.gov), on Boston Scientific's investor relations website (investors.bostonscientific.com/), or by contacting BSX Investor Relations. Details will also be provided in the forthcoming Form S-4 filing and related proxy statement/prospectus.

BSX 8-K: Regulation FD — Jan 15, 2026

Summary

Boston Scientific Corporation (BSX) has announced a significant development in its growth strategy through the execution of a definitive agreement to acquire Penumbra, Inc. This "Transaction", as detailed in a joint press release and investor presentation, represents a major move by BSX to expand its market presence and product portfolio. The company has scheduled a conference call to discuss the implications and details of this acquisition. Investors should pay close attention to the upcoming filings, including the Form S-4 registration statement, which will contain more comprehensive information regarding the deal and its potential impact on Boston Scientific's future.

Key Highlights

1Boston Scientific (BSX) has entered into a definitive agreement to acquire Penumbra, Inc.
2The acquisition is expected to be a key element of BSX's growth strategy.
3A joint press release and investor presentation have been issued to provide details on the transaction.
4BSX will host a conference call on January 15, 2026, at 8:00 a.m. ET to discuss the acquisition.
5The company will be filing a registration statement on Form S-4 with the SEC.
6Investors are urged to review the upcoming proxy statement/prospectus for detailed information on the transaction.

BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Jan 15, 2026)

Summary

Key Highlights

Frequently Asked Questions